Eribulin Mesylate Injection

The synthesis is extremely difficult and is known as the "Mount Everest" in the field of chemical and pharmaceutical synthesis

Eribulin Mesylate injection is indicated for patients with locally advanced or metastatic breast cancer who have previously received at least two chemotherapy regimens. As a new choice for yew and anthracycline resistance, it enables drug-resistant patients to achieve overall survival benefits, and is the preferred drug for advanced breast cancer. As the most difficult compound to synthesize in the synthetic world, the compound contains 19 chiral centers, theoretically 524,287 aberrations, and more than 65 synthetic steps, which is extremely difficult to synthesize, and is known as the " Everest" in the field of chemical and drug synthesis, with few competitors and good market prospects.

Indications:

For the treatment of patients with metastatic breast cancer who have received at least two previous treatment regimens, including anthracycline and taxane. 

For the treatment of patients with unresectable or metastatic liposarcoma who have been treated with anthracycline-containing drugs.

STRENGTH:

1mg/2mL